Systematic review: The association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 6, 2011, Pages 618-627

  Becher, A ^a   El Serag, H ^b  

^a OXFORD PHARMAGENESIS LTD   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ANXIETY; BLOATING; COUGHING; DISEASE SEVERITY; DYSPHAGIA; EPIGASTRIC PAIN; GASTROESOPHAGEAL REFLUX; HEALTH; HEARTBURN; HUMAN; MENTAL HEALTH; NAUSEA AND VOMITING; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SYSTEMATIC REVIEW; THORAX PAIN;

GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 80052038700     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04774.x     Document Type: Review

References (22)

1. El-Serag H, Becher A, Jones R,. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-37.
2. Donnellan C, Sharma N, Preston C, Moayyedi P,. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 4: CD003245.
3. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18: 767-76. (Pubitemid 37323641)
4. Pace F, Negrini C, Wiklund I, Rossi C, Savarino V,. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22: 349-56. (Pubitemid 41207465)
5. Hansen AN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B,. Long-term management of patients with symptoms of gastro-oesophageal reflux disease-a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract 2006; 60: 15-22. (Pubitemid 43732571)
6. Anvari M, Allen C,. Surgical outcome in gastro-esophageal reflux disease patients with inadequate response to proton pump inhibitors. Surg Endosc 2003; 17: 1029-35. (Pubitemid 36808092)
7. Brun J, Sorngard H,. High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care. Fam Pract 2000; 17: 401-4.
8. de Wit NJ, Boer WA, Geldof H, et al. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? Aliment Pharmacol Ther 2004; 20: 451-8. (Pubitemid 39120257)
9. Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G,. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care - prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther 2009; 29: 967-78.
10. Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104: 2005-13.
11. Hongo M, Kinoshita Y, Miwa H, Ashida K,. The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study. J Gastroenterol 2008; 43: 920-7.
12. Junghard O, Wiklund IK,. Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2007; 19: 555-60. (Pubitemid 46897298)
13. van der Velden AW, de Wit NJ, Quartero AO, Grobbee DE, Numans ME,. Maintenance treatment for GERD: residual symptoms are associated with psychological distress. Digestion 2008; 77: 207-13.
14. Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 41-9. (Pubitemid 29054907)
15. Derogatis LR, Rickels K, Rock AF,. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry 1976; 128: 280-9.
16. Wiklund I, Talley NJ,. Update on health-related quality of life in patients with gastroesophageal reflux disease. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3: 341-50. (Pubitemid 36722812)
17. Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO,. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 1621-30. (Pubitemid 30009080)
18. Wiklund I, Carlsson R, Carlsson J, Glise H,. Psychological factors as a predictor of treatment response in patients with heartburn: a pooled analysis of clinical trials. Scand J Gastroenterol 2006; 41: 288-93.
19. Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 443-52. (Pubitemid 47064372)
20. Ronkainen J, Aro P, Storskrubb T, et al. Impact of frequency of gastroesophageal reflux symptoms on health-related quality of life. Gut 2005; 54 (Suppl VII): A103-4.
21. Bytzer P,. What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment? Clin Gastroenterol Hepatol 2009; 7: 816-22.
22. Ware JE,. SF-36 Health Survey: Manual and Interpretation Guide. Boston: New England Medical Centre, 1993.